GU Cancers 2021 | Impact of intact P-Rmass on ICI response in mRCC

Hamid Emamekhoo, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, discusses the results of a retrospective analysis of 209 patients with metastatic renal cell carcinoma (mRCC) previously treated with first- or second-line immune checkpoint inhibitors (ICIs). The goal of this study was to investigate the impact of having an intact primary renal mass (P-Rmass) on response to systemic treatment with ICIs. The study found that the overall radiographic response to ICIs in the first- or second-line was numerically higher in patients with an intact P-Rmass compared to patients who had had nephrectomy, however this difference was not statistically significant. This interview took place during the 2021 Genitourinary Cancers Symposium.